Interferon beta-1b

Thông tin thuốc gốc
Chỉ định và Liều dùng
Relapsing remitting multiple sclerosis, Secondary progressive multiple sclerosis, Single demyelinating event suggestive of multiple sclerosis
Adult: Initially, 62.5 mcg (2 MIU) every other day, increased gradually over 3-6 wk to a target dose of 250 mcg/mL (8 MIU) every other day. Titration may be adjusted if significant AR occurs.
Hướng dẫn pha thuốc
Inject 1.2 mL of the diluent provided (NaCl 0.54%) into the vial labelled as containing 300 mcg (9.6 MIU) to produce a soln containing 250 mcg/mL (8 MIU). Swirl gently to dissolve.
Chống chỉ định
Hypersensitivity to natural or recombinant interferon beta or human albumin. Current severe depression and/or suicidal ideation, decompensated liver disease.
Thận trọng
Patient w/ previous or current depressive disorders, pre-existing CV disease, myelosuppression, thyroid dysfunction, history of seizure disorder. Hepatic impairment and severe renal failure. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Pancreatitis, hepatic injury (including hepatic failure), nephrotic syndrome, depression or suicidal ideation, CHF, immunogenicity, drug-induced lupus erythematosus, leucopenia, flu-like symptoms, severe hypersensitivity reactions (e.g. anaphylaxis, bronchospasm), inj site necrosis. Rarely, cardiomyopathy.
Nervous: Headache, incoordination, insomnia, asthenia, malaise.
CV: HTN, peripheral oedema.
GI: Abdominal pain.
Resp: Dyspnoea.
Hepatic: Increased SGOT/SGPT.
Genitourinary: Urinary urgency.
Endocrine: Impotence, metrorrhagia.
Haematologic: Decreased WBC, neutrophil, and lymphocyte counts.
Musculoskeletal: Hypertonia, myalgia.
Dermatologic: Rash, skin disorder.
Others: Lymphadenopathy, fever, pain.
Potentially Fatal: Thrombotic microangiopathy, systemic capillary leak syndrome (in patients w/ pre-existing monoclonal gammopathy).
IM/Parenteral/SC: C
Thông tin tư vấn bệnh nhân
May impair ability to drive or operate machinery.
Chỉ số theo dõi
Monitor CBC (including platelet count) and LFT at 1, 3, 6 mth following initiation of therapy and periodically thereafter. Assess thyroid function every 6 mth in patients w/ history of thyroid dysfunction or as clinically necessary. Monitor for flu-like symptoms, allergic reactions, inj site reactions, worsening of cardiac symptoms (in CHF patients) and for sign/symptoms of depression.
Tương tác
May decrease the metabolism of theophylline derivatives, except dyphylline. May decrease the metabolism and enhance the adverse effects of zidovudine.
Tác dụng
Mechanism of Action: Interferon beta-1b is a cytokine w/ antiviral and immunomodulating activities. Its exact mechanism in the treatment of multiple sclerosis is unknown. However, its biological response-modifying properties are mediated through its interaction w/ specific cell receptors. This induces the expression of gene products which are believed to be mediators of its pleiotropic bioactivities. Additionally, it decreases the binding affinity and enhances internalisation and degradation of interferon-γ receptor. It also enhances the suppressor activity of peripheral blood mononuclear cells.
Absorption: Bioavailability: Approx 50%. Time to peak plasma concentration: 1-8 hr.
Excretion: Elimination half-life: 8 min to 4.3 hr.
Bảo quản
Store between 20-25°C. Do not freeze.
Phân loại MIMS
Vaccin, kháng huyết thanh & thuốc miễn dịch
Phân loại ATC
L03AB08 - interferon beta-1b ; Belongs to the class of interferons. Used as immunostimulants.
Tài liệu tham khảo
Anon. Interferon Beta-1b. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/06/2017.

Anon. Interferon Beta. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 05/06/2017 .

Buckingham R (ed). Interferon Beta. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/06/2017 .

Extavia (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/06/2017 .

Extavia (Novartis Pharmaceuticals UK Ltd). eMC. Accessed 05/06/2017 .

Joint Formulary Committee. Interferon Beta. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 05/06/2017 .

Rossi S (ed). Interferon Beta. Australian Medicines Handbook [online]. Adelaide. Australian Medicines Handbook Pty Ltd. Accessed 05/06/2017 .

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Interferon beta-1b từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in